Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S.
Bumma N, et al. Among authors: mian h.
Cancer. 2023 Jul 15;129(14):2179-2191. doi: 10.1002/cncr.34778. Epub 2023 Apr 6.
Cancer. 2023.
PMID: 37021929